Consultant Specialist Physician and Endocrinologist, Private Practice, Claremont, Cape Town (since 1987)
Life Member College of Medicine, South Africa
Endocrine Consultant to the Kingsbury Hospital Surgical Obesity Clinic (Cape Town Surgical Bariatric Centre)
Accredited Insulin Pump Centre
Clinical Trial Centre (GCP accredited) (Good Clinical Practice)
Clinical Trial Centre: Participation (Principal Investigator) in clinical trials:
- 2000 H6E-MC-GLAG PI
- 2001 H6E-MC-GLAL PI
- 2001 Direct Study – Astra Zeneca PI
- 2002 CDJN608B2302 Navigator Study – Novartis PI
- 2004 BIAsp-1579 – Novo Nordisk PI
- 2004 D6160C00032 Gallant 7 -Astra Zeneca PI
- 2005 CLAF237A2310 Novartis PI
- 2006 CV-181-040 BMS PI
- 2006 IRIS study CL3-00780 SERVIER PI
- 2011 Servier CL3 00780-150: Follow up of study CL-00780 PI
- 2012 Novo Nordisk Study: BEGIN NN1250-3944 The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification PI
- 2014 DEVOTE study EX 1250-4080 A Study Comparing Cardiovascular Safety Of Insulin Degludec Versus Insulin Glargine In Subjects With Type 2 Diabetes At High Risk OF Cardiovascular Events PI
- 2014 EXSCEL study BCB109 A Randomized, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes PI
- 2014 MYLAN 2 Study MYL-GAI-3002 An Open Label, Randomized,
- Multi-Centre Parallel Group Clinical Trial Comparing the Efficacy and Safety of Mylan’s Insulin Glargine with Lantus In Type 2 Diabetes Mellitus Patients PI
- 2014 MYLAN 1 Study MYL-GAI-3001 An Open Label, Randomized, Multi-Centre Parallel Group Clinical Trial Comparing Efficacy and Safety Of Mylan’s Insulin Glargine With Lantus In Type 1 Diabetes Mellitus Patients PI
- 2016 BI Study (EASE-3) A Phase 3, randomised, double blind, placebo-controlled, parallel group efficacy safety and tolerability trial of once daily oral dose of Empagliflozin as Adjunctive to insulin therapy over 26 weeks in patients with type 1 Diabetes Mellitus PI
- Sanofi-Aventis Registry Study 14510 Wave 7 Registry study National PI
- 2016 DUAL Study NN9068-4228 DUAL 8-Duarability. A 104 – week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IdegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus PI
- 2016-2017 BI 1234.72 A phase 3 randomized, double blind, placebo controlled, parallel-group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin Adjunctive to Insulin Therapy over 26 weeks in patients with Type 1 Diabetes Mellitus
- Wave 7 Study (Sanofi)
- 2018-2019 Amplitude-O study: Sanofi EFC 14828 A randomized, double blind placebo controlled parallel group, multicentre study to evaluate the effect of Efpeglanatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk.
Journal references:
First author “Incidence of hypoglycaemia in the South African population: Results of the IDMPS Wave_7 study
First author “Management of patients with diabetes in the South African private healthcare sector-Results from the International Diabetes Management Practices Study Wave 7
Publications:
Incidence of Hypoglycaemia in the South African population with Diabetes: results from the IDMPS Wave 7 Study
Senior Academy Member CDE (Centres of Diabetes and Endocrinology- Diabetes Managed Care Program) (South Africa)
Member of SEMDSA (Society of Endocrinology, Metabolism and Diabetes SA); Faculty of Consulting Physicians (SAPPF)
(Previous Memberships: South African Hypertension Society; LASSA (Lipid and Atherosclerosis Society South Africa); South African Clinical Endocrinologist Subgroup of SEMDSA; consultant to Western Cape Adoption Panel)
Pharmaceutical Advisory Boards (previous or current): Novo Nordisk, Eli Lilly, Sanofi Aventis, Boehringer Ingelheim, MSD, Novartis.
Diabetes Education Advisory Panel Group, Johnson and Johnson Diabetes Education Institute, Paris (2008)
Contributed to the South African Guidelines for Type 2 Diabetes 2017
Regular attendance at National and International Conferences. Actively involved in local and national Continuing Medical Education meetings and workshops, lecturing to doctors and other groups on various topics especially in the field of Diabetes.
Previously a reviewer for Journal of Endocrinology, Metabolism and Diabetes of South Africa
2017 Contributed to the 2017 South African Guidelines for Type 2 Diabetes.
2007 Advanced course in Constant Glucose Monitoring, Medtronic, Switzerland.
2002 Postgraduate course in Endocrinology at Harvard University, Boston
1996 Sub-Specialist Registration – Certification Endocrinology and Metabolism
1988 M. Med (UCT) (Int. Med)
1987 Specialist private practice, Claremont, Cape Town
1986-1988 Senior Consultant, Hypertension Clinic, Groote Schuur Hospital
1986-1987 Consultant, Dept Medicine, Groote Schuur Hospital, Cape Town
1984-1987 Senior Registrar, Endocrine Dept, Groote Schuur Hospital, Cape Town
1983 FCP (SA) Internal Medicine
1981-1984 Registrar in Medicine, Baragwanath Hospital and Johannesburg General Hospital
1980 -1981 Senior Medical Officer Emergency Unit, Johannesburg Hospital
1978-1980 – worked at H.C. Boshoff Mission Hospital, Lebowa; Kataturra Hospital, Windhoek; Mbongolwani Mission Hospital, KwaZulu Natal
1977- ECFMG (Educational Commission for Foreign Medical Graduates)
1977 Internship, Johannesburg General Hospital; 1976 MB B.Ch (Wits University)
1976 MB B.Ch (University Witwatersrand)
